Author: Mark Newman

Share

Endocrine Society, Keystone Symposia to Host First Joint Conference in October 

Researchers can register and submit abstracts for the first joint meeting hosted by the Endocrine Society and Keystone Symposia — an intimate meeting designed to bring together researchers to advance understanding of how hormonal signaling shapes cancer risk, progression and treatment response.   Hormonal Influences on Immunity and Cancer Across the Lifespan, taking place in October in Breckenridge, Colo., will be the first of three joint meetings held by the organizations, which...
Share

Pharma Friday – May 15, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution On May 13, Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its...
Share

ENDO 2026 Preview: Beyond Basic DXA

At ENDO 2026, taking place June 13 – 16 in Chicago, “Beyond Basic DXA” is set to challenge how clinicians think about bone health assessment. Angela M. Cheung, MD, PhD, a professor of medicine at the University Health Network and the University of Toronto, will lead “Beyond Basic DXA” on Day 4 (Monday, June 15),...
Share

Widespread Chemicals in Plastics May Be Linked to Developmental Delays in Baby Girls

Exposure to common endocrine-disrupting chemicals (EDCs) during pregnancy may significantly alter the reproductive development of female infants during their first months of life, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Researchers found that daughters of women with higher concentrations of certain chemicals in their systems during pregnancy exhibited...
Share

Polyendocrine Metabolic Ovarian Syndrome: New Name to Improve Diagnosis and Care of Condition Affecting 170 Million Women Worldwide 

Global effort changes the name of a significant women’s health condition that was misunderstood to be ‘all about ovarian cysts’ Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition previously known as Polycystic Ovary Syndrome (PCOS), which impacts one in eight, or more than 170 million women worldwide.  More than 50 patient and professional organizations, including the Endocrine...
Share

Strategic Shifts: New Research Defines Best Ways to Switch Osteoporosis Meds

Effective long-term management of osteoporosis requires a carefully choreographed sequence of medications, as certain drug transitions can significantly enhance or inadvertently undermine bone density, according to a clinical review published by researchers at Aarhus University. The article, “Approach to the Patient—Transitions in Osteoporosis Therapy,” appearing in The Journal of Clinical Endocrinology & Metabolism, emphasizes that...